杨宁介入医学网

1. 适应症的选择 2. 客观反应率和整体生存率的关系 3. 剂量的选择（personalized dosimetry） 4. 结直肠癌肝转移剂量反应和剂量毒性【 Alsultan 2021 】 positive trend for most laboratory parameters and healthy liver-absorbed dose 大多数实验室参数和...

upcoming date New DATA CIRSE 2021...

欧洲医学肿瘤学会(ESMO)和（美国）国家综合癌症网络指南(NCCN)最近将介入治疗纳入了治疗结肠直肠癌(CRC)少转移性疾病(OMD)的标准治疗方法 ESMO指南 所谓少转移性疾病或者称寡转移性疾病（oligometastatic disease，OMD）是指数量和分布有限的远处转移性疾病状...

TACE术后病人的随访包括临床和影像 BCLC staging and treatment strategy, 2012 Forner, et al. Lancet. 2012 Mar 31;379(9822):1245-55. 为什么说TACE是中期肝癌的标准治疗 *P values refer to cumulative meta-analysis of five and six studies, respecti ...

尽管标准化的HAIC技术是评估HAIC安全性和疗效的重要因素，但HAIC技术的异质性仍然是评价这一技术的争议之一。 许多HAI化疗技术可以通过放置一个输液港-导管系统来进行。 在过去，输液导管是通过剖腹手术植入的，但患者暴露于与剖腹手术和全身麻醉相关的风险。...

简介 Hepatic artery infusion chemotherapy (HAIC) is a treatment modality for advanced hepatocellular carcinoma (HCC). 肝动脉输注化疗(HAIC)是治疗晚期肝癌(HCC)的一种治疗方式。 HAIC entails infusing chemotherapeutic agents directly into hepat...

The following characteristics of HAIC render it a suitable candidate for combination with other antineoplastic agents for advanced HCC: it is associated with fewer systemic adverse events compared with intravenous chemotherapy, and its cyt...

参与此项治疗的介入医生、外科医生和肿瘤内科医生应详知HAIC（经动脉灌注化疗）方法，原理，相关并发症和病人管理。 Work-upPreoperative imaging included cross-sectional imaging with computed tomography (CT) and/or magnetic resonance imaging (MRI)...

Lack of Industry Incentive for Conducting Trials 开展试验缺乏行业激励 The patents for the main chemotherapeutic agents used in HAIC, including cisplatin, oxaliplatin, 5-FU, and epirubicin, have expired, thus weakening the motivation for th...

Insufficient Technical Standardization Techniques and protocols for HAIC have yet to be standardized. HAIC的技术和方案尚未标准化。 The efficacy and safety of HAIC depend substantially on the quality of vascular redistribution. HAIC的有效性...